Abstract
Introduction Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disease primarily affecting extraocular, bulbar, axial, and proximal extremity muscle groups. However, a subgroup of patients experience distal extremity weakness, known as distal myasthenia gravis (DMG). Despite its longtime observation, DMG’s clinical and demographic features remain poorly understood. This scoping review aims to summarise current evidence regarding the demographic, clinical, and diagnostic features of autoimmune MG patients who exhibit atypical, distal extremity weakness.
Methods We conducted a scoping review by searching the following electronic databases: Embase, Medline (Ovid), Scopus, Web of Science, and ResearchGate, covering the period from their inception up to August 2024. We included all types of publications due to the limited number of articles available on DMG. Since we wanted to work on individual-level patient data, we selected papers based on our inclusion and exclusion criteria, and interpreted the data descriptively.
Results After the screening of the initial 2162 publications, we assessed 55 for eligibility. 23 articles (11 case reports, 5 letters to the editor, 2 poster abstracts, and 5 case series) fulfilled the inclusion and exclusion criteria. Demographic and clinical details of 43 patients were extracted for further analysis. The male-to-female ratio was 1.4:1, with a mean (SD) age of MG onset at 40.2 ± 17.2 and a mean age of DMG onset at 44.9 ± 16.3. As 38% DMG patients developed distal extremity weakness at disease onset, in total 55% of DMG patients showed distal symptoms within the first year of their diagnosis. In women with DMG, generalised MG was often present at disease onset (83%), whereas men had similar percentages of ocular (52%) and generalised (48%) MG at disease onset. The most frequently reported weaknesses were in finger extension, followed by wrist extension, elbow extension, and finger abduction. Ankle dorsiflexion weakness was the most frequently reported form of distal lower extremity weakness.
Conclusion Distal myasthenia gravis (DMG) is a rare yet debilitating subtype of myasthenia gravis. When evaluating MG patients with distal symptoms, it is crucial to consider various differential diagnoses resulting in distal extremity weakness. In this context, we would like to emphasise two MG-associated conditions, namely myasthenia-inflammatory myopathy (MG-IM) and myasthenic neuromyopathy. Our scoping review highlights the need for future prospective studies to address unanswered questions to improve clinical outcomes and the quality of life for patients with DMG.
Highlights
Significant weakness of distal extremity muscles is rare (3-7%) in myasthenia gravis (MG) and is known as distal myasthenia gravis (DMG).
Finger and wrist extensors are the most frequently reported distal muscles affected in DMG.
Approximately 38% of the DMG patients in this review experienced distal extremity weakness at the onset of MG, and a total of 55% developed distal symptoms within the first year of the disease.
At disease onset, 83% of women with DMG presented with generalised MG, whereas men had similar percentages of ocular (52%) and generalised onset (48%).
When evaluating MG patients with distal symptoms, it is crucial to clinically consider two MG-associated conditions, namely myasthenia-inflammatory myopathy (MG-IM) and myasthenic neuromyopathy.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
As all analyses were conducted using previously published studies, ethical approval and patient consent are not required. A full list of studies the data is taken from, can be found in the supplementary file (S1_Appendix_Search_Strategy) under included articles.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Abbreviations
- AChR
- Acetylcholine receptor
- DMG
- Distal myasthenia gravis
- EMG
- Electromyography
- MG
- Myasthenia gravis
- OCEBM
- Oxford Centre for Evidence-Based Medicine
- RNS
- Repetitive nerve stimulation
- MSA
- Myositis-specific autoantibodies
- MAA
- Myositis-associated autoantibodies
- CK
- Creatine kinase
- MG-IM
- Myasthenia gravis with inflammatory myopathy
- LEMS
- Lambert-Eaton myasthenic syndrome
- QMGS
- Quantitative myasthenia gravis score
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.